טוען...

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial

AIMS: Hypoglycaemia, in patients with Type 2 diabetes (T2D) is associated with an increased risk for cardiovascular (CV) events. In EMPA-REG OUTCOME, the sodium-glucose co-transporter-2 inhibitor empagliflozin reduced the risk of CV death by 38% and heart failure hospitalization (HHF) by 35%, while...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	Eur Heart J
Main Authors:	Fitchett, David, Inzucchi, Silvio E, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Vedin, Ola, Zinman, Bernard, Johansen, Odd Erik
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Oxford University Press 2020
נושאים:	Fast Track Clinical Research
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6945517/ https://ncbi.nlm.nih.gov/pubmed/31504427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehz621
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial

פריטים דומים